Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Elite Pharmaceuticals, Inc. (ELTP)
USD0.37
0.00 (-0.51%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
165 Ludlow Avenue 7647
Northvale, NJ, US
Northvale, NJ, US
CEO
Nasrat Hakim
Website
elitepharma.com
IPO
2000-02-24
CIK 1053369 ISIN US28659T2006
Description
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.37
0.00 (-0.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
576.5K
Beta
0.38
Float Shares
835.88M
Free Float %
77.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.45% | -1.45% | +0.00% | -17.07% | -36.10% | -30.65% | -37.04% | +871.43% | +466.67% | +6.25% | -97.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.37
DCF (Unlevered)
0.08
-79.7%
DCF (Levered)
0.18
-51.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.77
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+77.1% ★ Q1'26: +27.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+912.5% ★ Q1'26: -37.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.5% Q1'26: +21.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+33.6% ★ Q1'26: +27.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: -0.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.6% Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.11× ★ Q1'26: 0.13× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2011 actual |
|---|---|
| Revenue |
4.27M
est: 30.31M (-85.9%)
|
| EBITDA |
-11.91M
est: 2.56M (-564.7%)
|
| EBIT |
-12.39M
est: 1.62M (-864.5%)
|
| Net Income |
-13.58M
|
| SGA |
876.0K
est: 4.00M (-78.1%)
|
| EPS |
-0.14
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
17.38M
OE per share TTM
0.02
Owner's Yield
4.70%
Maintenance CapEx ratio
0.92%
Maint CapEx / Avg PPE
0.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
180.00
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NASRAT HAKIM | 267.27M | 24.20% | 267.27M | — | 267.27M | — | IN | UNITED STATES | 2020-09-01 | ↗ |
| 2 | MIKAH PHARMA LLC | 142.86M | 17.80% | 142.86M | — | 142.86M | — | OO | DELAWARE | 2015-07-16 | ↗ |
| 3 | Ashok G. Nigalaye | 120.00M | 60.39% | — | — | — | — | IN | or Place of Organization | 2009-11-05 | ↗ |
| 4 | Epic Investments, LLC (90-0486059) | 120.00M | 60.39% | — | — | — | — | OO | or Place of Organization | 2009-11-05 | ↗ |
| 5 | Epic Pharma, LLC (32-0254130) | 120.00M | 60.39% | — | — | — | — | OO | or Place of Organization | 2009-11-05 | ↗ |
| 6 | Jeenarine Narine | 120.00M | 60.39% | — | — | — | — | IN | or Place of Organization | 2009-11-05 | ↗ |
| 7 | Ram Potti | 120.00M | 60.39% | — | — | — | — | IN | or Place of Organization | 2009-11-05 | ↗ |
| 8 | NAME OF REPORTING | 17.54M | 17.91% | — | 17.54M | — | 17.54M | OO | USA | 2011-02-14 | ↗ |
| 9 | Wilson Earl Gilliam, Jr. | 15.00M | 3.90% | 15.00M | — | 15.00M | — | IN | United States of America | 2013-01-08 | ↗ |
| 10 | Investment Ltd. | 7.49M | 7.68% | 7.49M | — | 7.49M | — | OO | Bermuda | 2011-02-15 | ↗ |
| 11 | Anthony A. Yoseloff | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 12 | Avram Z. Friedman | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 13 | Conor Bastable | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 14 | DK Group LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2010-02-16 | ↗ |
| 15 | DK Management Partners LP | — | 0.00% | — | — | — | — | PN | Delaware | 2010-02-16 | ↗ |
| 16 | DK Stillwater GP LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2010-02-16 | ↗ |
| 17 | Davidson Kempner Advisers Inc. | — | 0.00% | — | — | — | — | IA | New York | 2010-02-16 | ↗ |
| 18 | Davidson Kempner Healthcare Fund LP | — | 0.00% | — | — | — | — | PN | Delaware | 2010-02-16 | ↗ |
| 19 | Davidson Kempner Healthcare International Ltd. | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2010-02-16 | ↗ |
| 20 | Davidson Kempner Institutional Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2010-02-16 | ↗ |
| 21 | Davidson Kempner International Advisors, L.L.C. | — | 0.00% | — | — | — | — | OO | Delaware | 2010-02-16 | ↗ |
| 22 | Davidson Kempner International, Ltd. | — | 0.00% | — | — | — | — | CO | British Virgin Islands | 2010-02-16 | ↗ |
| 23 | Davidson Kempner Partners | — | 0.00% | — | — | — | — | PN | New York | 2010-02-16 | ↗ |
| 24 | Eric P. Epstein | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 25 | M. H. Davidson & Co. | — | 0.00% | — | — | — | — | PN | New York | 2010-02-16 | ↗ |
| 26 | MHD Management Co. | — | 0.00% | — | — | — | — | PN | New York | 2010-02-16 | ↗ |
| 27 | Marvin H. Davidson | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 28 | Michael J. Leffell | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 29 | Robert J. Brivio, Jr. | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 30 | Scott E. Davidson | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 31 | Stephen M. Dowicz | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 32 | Thomas L. Kempner, Jr. | — | 0.00% | — | — | — | — | IN | United States | 2010-02-16 | ↗ |
| 33 | Timothy I. Levart | — | 0.00% | — | — | — | — | IN | United Kingdom & United States | 2010-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | KELLEHER FINANCIAL ADVISORS | 500.00 +— (+0.0%) | 180.00 -65.0 (-26.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.64 -43.8% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
800.0K
Cash buys
—
Cash sales
1.00
Net activity
-800,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | Plassche Douglas | Officer | M-Exempt | A | Stock Options (right to buy) | 2,500,000 | 0.03 | 75.0K | 6,000,000 | D | ↗ |
| 2025-10-02 | Plassche Douglas | Officer | S-Sale | D | common stock | 800,000 | 0.62 | 499.2K | 3,500,000 | D | ↗ |
| 2025-08-25 | ELITE PHARMACEUTICALS INC /NV/ | Officer | M-Exempt | A | Common Stock | 2,500,000 | 0.03 | 75.0K | 4,300,000 | D | ↗ |
| 2025-08-22 | ELITE PHARMACEUTICALS INC /NV/ | Officer | S-Sale | D | Common Stock | 500,000 | 0.52 | 262.2K | 1,800,000 | D | ↗ |
| 2025-07-10 | Kirkov Kirko | Officer | P-Purchase | A | Common Stock | 16,366 | 0.59 | 9.6K | 16,366 | D | ↗ |
| 2025-07-08 | Plassche Douglas | Officer | S-Sale | D | Stock Options (right to buy) | 200,000 | 0.58 | 115.8K | 2,300,000 | D | ↗ |
| 2025-07-03 | Plassche Douglas | Officer | M-Exempt | D | Stock Options (right to buy) | 2,500,000 | 0.03 | 75.0K | 5,000,000 | D | ↗ |
| 2024-10-24 | Plassche Douglas | Officer | S-Sale | D | Common Stock | 333,932 | 0.51 | 170.3K | 0 | D | ↗ |
| 2024-10-23 | Plassche Douglas | Officer | S-Sale | D | Common Stock | 800,000 | 0.49 | 392.0K | 333,932 | D | ↗ |
| 2024-03-29 | Hakim Nasrat A | Director / Officer / 10% Owner | A-Award | A | Common Stock | 49,534,368 | 0.00 | — | 216,649,250 | — | ↗ |
| 2023-12-29 | Hakim Nasrat A | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-22 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 547,657 | 0.04 | 20.0K | 3,187,020 | — | ↗ |
| 2023-11-22 | Dash Barry H | Director | A-Award | A | Common Stock | 547,657 | 0.04 | 20.0K | 3,235,555 | — | ↗ |
| 2023-11-22 | Caskey Davis S | Director | A-Award | A | Common Stock | 547,657 | 0.04 | 20.0K | 2,049,436 | — | ↗ |
| 2023-05-01 | Pellegrino Mark N | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | Plassche Douglas | Officer | A-Award | A | Options | 7,500,000 | 0.03 | 225.0K | 7,500,000 | — | ↗ |
| 2022-09-06 | Kirkov Kirko | Officer | A-Award | A | Options | 3,000,000 | 0.04 | 105.0K | 3,000,000 | — | ↗ |
| 2022-08-28 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 459,536 | 0.04 | 20.0K | 2,639,363 | — | ↗ |
| 2022-08-28 | Dash Barry H | Director | A-Award | A | Common Stock | 459,536 | 0.04 | 20.0K | 2,687,898 | — | ↗ |
| 2022-08-28 | Caskey Davis S | Director | A-Award | A | Common Stock | 459,536 | 0.04 | 20.0K | 1,501,779 | — | ↗ |
| 2022-05-16 | Chen Robert C J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-30 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 295,570 | 0.07 | 20.0K | 2,179,827 | — | ↗ |
| 2021-06-30 | Dash Barry H | Director | A-Award | A | Common Stock | 295,570 | 0.07 | 20.0K | 2,228,182 | — | ↗ |
| 2021-06-30 | Caskey Davis S | Director | A-Award | A | Common Stock | 295,570 | 0.07 | 20.0K | 1,042,243 | — | ↗ |
| 2021-05-17 | Bregman Marc | Officer | A-Award | A | Options | 300,000 | 0.06 | 16.9K | 300,000 | — | ↗ |
| 2020-08-24 | Hakim Nasrat A | Director / Officer / 10% Owner | C-Conversion | D | Series J Convertible Preferred Shares | 24 | 0.00 | — | 0 | — | ↗ |
| 2020-08-20 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 516,781 | 0.09 | 45.0K | 1,884,257 | — | ↗ |
| 2020-08-20 | Plassche Douglas | Officer | A-Award | A | Common Stock | 71,739 | 0.09 | 6.3K | 1,133,932 | — | ↗ |
| 2020-08-20 | Dash Barry H | Director | A-Award | A | Common Stock | 516,781 | 0.09 | 45.0K | 1,932,612 | — | ↗ |
| 2020-08-20 | Caskey Davis S | Director | A-Award | A | Common Stock | 516,781 | 0.09 | 45.0K | 746,673 | — | ↗ |
| 2020-06-30 | Plassche Douglas | Officer | A-Award | A | Common Stock | 574,597 | 0.09 | 50.0K | 1,062,193 | — | ↗ |
| 2018-02-26 | Ward Carter Julian | Officer | A-Award | A | Common Stock | 242,060 | 0.12 | 30.0K | 2,127,364 | — | ↗ |
| 2018-02-26 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 161,374 | 0.12 | 20.0K | 1,367,476 | — | ↗ |
| 2018-02-26 | Plassche Douglas | Officer | A-Award | A | Common Stock | 201,717 | 0.12 | 25.0K | 487,596 | — | ↗ |
| 2018-02-26 | Pfeifer Eugene M | Director | A-Award | A | Common Stock | 161,374 | 0.12 | 20.0K | 233,414 | — | ↗ |
| 2018-02-26 | Dash Barry H | Director | A-Award | A | Common Stock | 161,374 | 0.12 | 20.0K | 1,415,831 | — | ↗ |
| 2018-02-26 | Caskey Davis S | Director | A-Award | A | Common Stock | 161,374 | 0.12 | 20.0K | 229,892 | — | ↗ |
| 2017-04-28 | Hakim Nasrat A | Director / Officer / 10% Owner | J-Other | A | Warrants | 79,008,661 | 0.15 | 12.02M | 79,008,661 | — | ↗ |
| 2017-02-23 | Ward Carter Julian | Director | A-Award | A | Common Stock | 133,019 | 0.23 | 30.0K | 1,885,304 | — | ↗ |
| 2017-02-23 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 88,679 | 0.23 | 20.0K | 1,206,102 | — | ↗ |
| 2017-02-23 | Plassche Douglas | Officer | A-Award | A | Common Stock | 110,849 | 0.23 | 25.0K | 285,879 | — | ↗ |
| 2017-02-23 | Pfeifer Eugene M | Director | A-Award | A | Common Stock | 72,040 | 0.20 | 14.6K | 72,040 | — | ↗ |
| 2017-02-23 | Hakim Nasrat A | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,216,992 | 0.23 | 499.9K | 24,143,785 | — | ↗ |
| 2017-02-23 | Dash Barry H | Director | A-Award | A | Common Stock | 88,679 | 0.23 | 20.0K | 1,254,457 | — | ↗ |
| 2017-02-23 | Caskey Davis S | Director | A-Award | A | Common Stock | 68,518 | 0.20 | 13.4K | 68,518 | — | ↗ |
| 2016-08-17 | Hakim Nasrat A | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 142,857,143 | 0.00 | — | 142,971,097 | — | ↗ |
| 2016-04-28 | Ward Carter Julian | Officer | C-Conversion | A | Common Stock | 666,667 | 0.06 | 41.7K | 1,752,285 | — | ↗ |
| 2016-04-28 | Caskey Davis S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-13 | NARINE JEENARINE | — | C-Conversion | A | Common Stock | 4,000,000 | 0.06 | 250.0K | 16,742,395 | — | ↗ |
| 2016-04-07 | Pfeifer Eugene M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-18 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 258,090 | 0.34 | 88.3K | 7,640,561 | — | ↗ |
| 2016-03-17 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 312,430 | 0.35 | 107.8K | 7,898,651 | — | ↗ |
| 2016-02-24 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 100,456 | 0.31 | 31.1K | 8,211,081 | — | ↗ |
| 2016-02-22 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 100,000 | 0.32 | 32.1K | 8,311,537 | — | ↗ |
| 2016-02-17 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 50,000 | 0.31 | 15.6K | 8,411,537 | — | ↗ |
| 2016-02-16 | Ward Carter Julian | Officer | A-Award | A | Common Stock | 122,325 | 0.25 | 30.0K | 1,085,618 | — | ↗ |
| 2016-02-16 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 81,549 | 0.25 | 20.0K | 1,117,423 | — | ↗ |
| 2016-02-16 | TREPPEL JERRY | — | A-Award | A | Common Stock | 124,646 | 0.25 | 30.9K | 8,461,537 | — | ↗ |
| 2016-02-16 | Plassche Douglas | Officer | A-Award | A | Common Stock | 47,767 | 0.26 | 12.5K | 175,030 | — | ↗ |
| 2016-02-16 | NARINE JEENARINE | Director | A-Award | A | Common Stock | 81,549 | 0.25 | 20.0K | 12,742,395 | — | ↗ |
| 2016-02-16 | Hakim Nasrat A | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,854,279 | 0.25 | 699.9K | 22,040,747 | — | ↗ |
| 2016-02-16 | Dash Barry H | Director | A-Award | A | Common Stock | 81,549 | 0.25 | 20.0K | 1,165,778 | — | ↗ |
| 2016-02-05 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 24,400 | 0.33 | 8.1K | 8,336,891 | — | ↗ |
| 2016-02-04 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 349,660 | 0.32 | 111.9K | 8,361,291 | — | ↗ |
| 2016-02-03 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 45,518 | 0.33 | 15.0K | 8,710,951 | — | ↗ |
| 2016-02-02 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 13,000 | 0.33 | 4.3K | 8,756,469 | — | ↗ |
| 2016-02-01 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 312,300 | 0.34 | 106.2K | 8,769,469 | — | ↗ |
| 2016-01-29 | TREPPEL JERRY | — | S-Sale | D | Common Stock | 115,000 | 0.35 | 40.3K | 9,081,769 | — | ↗ |
| 2015-12-31 | NARINE JEENARINE | Director | G-Gift | D | Common Stock | 6,000,000 | 0.00 | — | 12,262,006 | — | ↗ |
| 2015-11-18 | TREPPEL JERRY | Director / Officer | S-Sale | D | Common Stock | 25,000 | 0.31 | 7.6K | 9,196,769 | — | ↗ |
| 2015-11-17 | TREPPEL JERRY | Director / Officer | S-Sale | D | Common Stock | 25,000 | 0.30 | 7.5K | 9,221,769 | — | ↗ |
| 2015-11-16 | TREPPEL JERRY | Director / Officer | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.1K | 9,246,769 | — | ↗ |
| 2015-11-13 | TREPPEL JERRY | Director / Officer | G-Gift | D | Common Stock | 7,500 | 0.31 | 2.3K | 9,346,769 | — | ↗ |
| 2015-10-30 | NARINE JEENARINE | Director | J-Other | A | Common Stock | 398,840 | 0.00 | — | 398,840 | — | ↗ |
| 2015-10-30 | Hakim Nasrat A | Director / Officer / 10% Owner | J-Other | A | common | 113,954 | 0.00 | — | 113,954 | — | ↗ |
| 2015-09-14 | NIGALAYE ASHOK G | Director | G-Gift | D | Warrant | 5,697,710 | 0.06 | 356.1K | 0 | — | ↗ |
| 2015-08-14 | Plassche Douglas | 10% Owner | A-Award | A | Common Stock | 54,169 | 0.23 | 12.5K | 127,263 | — | ↗ |
| 2015-06-02 | Hakim Nasrat A | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 2,741,801 | 0.06 | 171.4K | 5,311,819 | — | ↗ |
| 2015-05-21 | NIGALAYE ASHOK G | Director | C-Conversion | A | Common Stock | 2,000,000 | 0.06 | 125.0K | 40,442,232 | — | ↗ |
| 2015-05-05 | NIGALAYE ASHOK G | Director / 10% Owner | C-Conversion | A | Common Stock | 2,000,000 | 0.06 | 125.0K | 38,442,232 | — | ↗ |
| 2015-05-04 | NIGALAYE ASHOK G | Director / 10% Owner | G-Gift | D | Warrants | 350,000 | 0.06 | 21.9K | 1,324,333 | — | ↗ |
| 2015-04-27 | Plassche Douglas | Officer | S-Sale | D | Common Stock | 85,530 | 0.24 | 20.2K | 73,094 | — | ↗ |
| 2015-04-27 | EPIC PHARMA LLC | 10% Owner | J-Other | D | Common Stock | 67,659,232 | 0.00 | — | 0 | — | ↗ |
| 2015-04-23 | NIGALAYE ASHOK G | Director | J-Other | D | Common Stock | 67,659,232 | 0.00 | — | 0 | — | ↗ |
| 2015-04-23 | NARINE JEENARINE | Director | J-Other | D | Common Stock | 67,659,232 | 0.00 | — | 0 | — | ↗ |
| 2015-04-23 | Hakim Nasrat A | Director / Officer / 10% Owner | J-Other | A | Common Stock | 2,570,018 | 0.00 | — | 2,570,018 | — | ↗ |
| 2015-04-23 | EPIC INVESTMENTS, LLC | 10% Owner | J-Other | D | Common Stock | 67,659,232 | 0.00 | — | 0 | — | ↗ |
| 2015-04-16 | NIGALAYE ASHOK G | Director / 10% Owner | G-Gift | D | Warrants | 1,250,000 | 0.06 | 78.1K | 1,204,665 | — | ↗ |
| 2015-04-03 | NIGALAYE ASHOK G | Director / 10% Owner | J-Other | D | Warrants | 4,000,000 | 0.06 | 250.0K | 0 | — | ↗ |
| 2015-04-03 | NARINE JEENARINE | Director / 10% Owner | J-Other | D | Warrants | 4,000,000 | 0.06 | 250.0K | 0 | — | ↗ |
| 2015-04-03 | Hakim Nasrat A | Director / Officer / 10% Owner | J-Other | A | Warrants | 1,982,106 | 0.06 | 123.9K | 1,982,106 | — | ↗ |
| 2015-04-03 | EPIC PHARMA LLC | 10% Owner | J-Other | D | Warrants | 4,000,000 | 0.06 | 250.0K | 0 | — | ↗ |
| 2015-04-03 | EPIC INVESTMENTS, LLC | 10% Owner | J-Other | D | Warrants | 4,000,000 | 0.06 | 250.0K | 0 | — | ↗ |
| 2015-03-31 | Plassche Douglas | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-03-05 | Ward Carter Julian | Officer | A-Award | A | common | 87,711 | 0.34 | 30.0K | 963,293 | — | ↗ |
| 2015-03-05 | WHITNELL JEFFREY A | Director | A-Award | A | common | 58,475 | 0.34 | 20.0K | 1,035,874 | — | ↗ |
| 2015-03-05 | TREPPEL JERRY | Director / Officer | A-Award | A | common stock | 87,711 | 0.34 | 30.0K | 9,354,269 | — | ↗ |
| 2015-03-05 | NIGALAYE ASHOK G | Director / 10% Owner | A-Award | A | common | 58,475 | 0.34 | 20.0K | 17,167,097 | — | ↗ |
| 2015-03-05 | NARINE JEENARINE | Director / 10% Owner | A-Award | A | common | 58,475 | 0.34 | 20.0K | 5,568,930 | — | ↗ |
| 2015-03-05 | Hakim Nasrat A | Director / Officer / 10% Owner | A-Award | A | common | 2,046,554 | 0.34 | 699.9K | 13,760,695 | — | ↗ |
| 2015-03-05 | Dash Barry H | Director | A-Award | A | common | 58,475 | 0.34 | 20.0K | 1,084,229 | — | ↗ |
| 2015-01-06 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 2,833,333 | 0.06 | 177.1K | 17,108,622 | — | ↗ |
| 2014-10-17 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | J-Other | D | Warrants | 20,000,002 | 0.06 | 1.25M | 6,726,999 | — | ↗ |
| 2014-10-17 | NARINE JEENARINE | Director / 10% Owner | J-Other | A | Warrants | 4,178,320 | 0.06 | 261.1K | 8,602,653 | — | ↗ |
| 2014-10-17 | Hakim Nasrat A | Director / Officer / 10% Owner | J-Other | A | Warrants | 759,695 | 0.06 | 47.5K | 759,695 | — | ↗ |
| 2014-10-17 | EPIC PHARMA LLC | 10% Owner | J-Other | D | Warrants | 20,000,002 | 0.06 | 1.25M | 6,726,999 | — | ↗ |
| 2014-10-17 | EPIC INVESTMENTS, LLC | 10% Owner | J-Other | D | Warrants | 20,000,002 | 0.06 | 1.25M | 6,726,999 | — | ↗ |
| 2014-09-26 | Hakim Nasrat A | Director / Officer | P-Purchase | A | Common Stock | 265,500 | 0.31 | 82.4K | 2,700,000 | — | ↗ |
| 2014-09-25 | Hakim Nasrat A | Director / Officer | P-Purchase | A | Common Stock | 434,500 | 0.31 | 134.0K | 2,434,500 | — | ↗ |
| 2014-09-10 | TREPPEL JERRY | Director / Officer | C-Conversion | D | Series I Convertible Preferred Shares | 4 | 0.07 | 0.30 | 0 | — | ↗ |
| 2014-08-08 | NARINE JEENARINE | Director / 10% Owner | G-Gift | D | Warrants | 2,000,000 | 0.06 | 125.0K | 2,757,666 | — | ↗ |
| 2014-08-01 | Hakim Nasrat A | Director / Officer | — | D | Convertible Note | 142,857,143 | 0.07 | 10.00M | 0 | — | ↗ |
| 2014-06-17 | TREPPEL JERRY | Director / Officer | C-Conversion | A | Common Stock | 375,000 | 0.13 | 46.9K | 3,206,558 | — | ↗ |
| 2014-05-09 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 329,437 | 0.38 | 125.9K | 5,510,455 | — | ↗ |
| 2014-04-23 | Dash Barry H | Director | C-Conversion | A | Common Stock | 12,423 | 0.25 | 3.1K | 1,025,754 | — | ↗ |
| 2014-04-02 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 147,664 | 0.41 | 60.5K | 5,839,892 | — | ↗ |
| 2014-04-01 | NARINE JEENARINE | Director | S-Sale | D | Common Stock | 157,012 | 0.41 | 64.6K | 5,830,544 | — | ↗ |
| 2014-03-27 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 190,172 | 0.43 | 81.2K | 5,987,556 | — | ↗ |
| 2014-03-18 | TREPPEL JERRY | Director | — | I | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2014-03-12 | TREPPEL JERRY | Director / Officer | M-Exempt | A | Common Stock | 180,000 | 0.06 | 10.8K | 2,831,558 | — | ↗ |
| 2014-03-11 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 239,367 | 0.60 | 144.0K | 20,300,770 | — | ↗ |
| 2014-03-11 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 239,367 | 0.60 | 144.0K | 14,887,229 | — | ↗ |
| 2014-03-11 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 239,367 | 0.60 | 144.0K | 67,669,232 | — | ↗ |
| 2014-03-11 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 239,367 | 0.60 | 144.0K | 67,669,232 | — | ↗ |
| 2014-03-07 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,051,450 | 0.68 | 715.0K | 20,372,580 | — | ↗ |
| 2014-03-07 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 1,051,450 | 0.68 | 715.0K | 14,939,890 | — | ↗ |
| 2014-03-07 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 1,051,450 | 0.68 | 715.0K | 67,908,599 | — | ↗ |
| 2014-03-07 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 1,051,450 | 0.68 | 715.0K | 67,908,599 | — | ↗ |
| 2014-03-06 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 773,050 | 0.90 | 692.3K | 20,688,015 | — | ↗ |
| 2014-03-06 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 773,050 | 0.90 | 692.3K | 15,171,209 | — | ↗ |
| 2014-03-06 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 773,050 | 0.90 | 692.3K | 68,960,049 | — | ↗ |
| 2014-03-06 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 773,050 | 0.90 | 692.3K | 68,960,049 | — | ↗ |
| 2014-02-25 | Ward Carter Julian | Officer | A-Award | A | Common Stock | 330,159 | 0.09 | 30.0K | 875,582 | — | ↗ |
| 2014-02-25 | WHITNELL JEFFREY A | Director | A-Award | A | Common Stock | 220,106 | 0.09 | 20.0K | 977,399 | — | ↗ |
| 2014-02-25 | TREPPEL JERRY | Director / Officer | A-Award | A | Common Stock | 330,159 | 0.09 | 30.0K | 2,760,006 | — | ↗ |
| 2014-02-25 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | C-Conversion | D | Warrants | 2,000,000 | 0.06 | 125.0K | 1,333,333 | — | ↗ |
| 2014-02-25 | NARINE JEENARINE | Director / 10% Owner | A-Award | A | Common Stock | 220,106 | 0.09 | 20.0K | 6,177,728 | — | ↗ |
| 2014-02-25 | Hakim Nasrat A | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,616,580 | 0.11 | 291.5K | 11,714,141 | — | ↗ |
| 2014-02-25 | Dash Barry H | Director | A-Award | A | Common Stock | 220,106 | 0.09 | 20.0K | 1,013,331 | — | ↗ |
| 2014-02-07 | TREPPEL JERRY | Director / Officer | C-Conversion | A | Series I Convertible Preferred Shares | 4 | 141,442.72 | 600.0K | 4 | — | ↗ |
| 2014-02-07 | Hakim Nasrat A | Director / Officer / 10% Owner | C-Conversion | A | Series I Convertible Preferred Shares | 100 | 100,000.00 | 10.00M | 100 | — | ↗ |
| 2014-01-13 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 805,583 | 0.18 | 147.4K | 20,919,930 | — | ↗ |
| 2014-01-13 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 805,583 | 0.18 | 147.4K | 15,341,280 | — | ↗ |
| 2014-01-13 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 805,583 | 0.18 | 147.4K | 69,733,099 | — | ↗ |
| 2014-01-13 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 805,538 | 0.18 | 147.4K | 69,733,099 | — | ↗ |
| 2013-12-05 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 275,000 | 0.13 | 34.5K | 21,301,460 | — | ↗ |
| 2013-12-05 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 275,000 | 0.13 | 34.5K | 15,621,069 | — | ↗ |
| 2013-12-05 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 275,000 | 0.13 | 34.5K | 71,004,867 | — | ↗ |
| 2013-12-05 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 275,000 | 0.13 | 34.5K | 71,004,867 | — | ↗ |
| 2013-12-02 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.13 | 12.5K | 21,391,048 | — | ↗ |
| 2013-12-02 | NARINE JEENARINE | Director / 10% Owner | D-Return | D | Common Stock | 100,000 | 0.13 | 12.5K | 15,686,768 | — | ↗ |
| 2013-12-02 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.13 | 12.5K | 71,303,493 | — | ↗ |
| 2013-12-02 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.13 | 12.5K | 71,303,493 | — | ↗ |
| 2013-11-27 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.12 | 3.0K | 21,421,048 | — | ↗ |
| 2013-11-27 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.12 | 3.0K | 15,708,769 | — | ↗ |
| 2013-11-27 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.12 | 3.0K | 71,403,493 | — | ↗ |
| 2013-11-27 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 25,000 | 0.12 | 3.0K | 71,403,493 | — | ↗ |
| 2013-11-26 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 357,000 | 0.12 | 43.1K | 21,428,528 | — | ↗ |
| 2013-11-26 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 23,626 | 0.12 | 2.8K | 15,681,569 | — | ↗ |
| 2013-11-26 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 357,000 | 0.12 | 43.1K | 71,428,493 | — | ↗ |
| 2013-11-26 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 357,000 | 0.12 | 43.1K | 71,428,493 | — | ↗ |
| 2013-11-19 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 21,000 | 0.12 | 2.5K | 21,547,348 | — | ↗ |
| 2013-11-19 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 21,000 | 0.12 | 2.5K | 15,801,388 | — | ↗ |
| 2013-11-19 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 21,000 | 0.12 | 2.5K | 71,824,493 | — | ↗ |
| 2013-11-19 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 21,000 | 0.12 | 2.5K | 71,824,493 | — | ↗ |
| 2013-11-18 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,170,000 | 0.12 | 137.5K | 21,553,648 | — | ↗ |
| 2013-11-18 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 1,170,000 | 0.12 | 137.5K | 15,806,008 | — | ↗ |
| 2013-11-18 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 1,170,000 | 0.12 | 137.5K | 71,845,493 | — | ↗ |
| 2013-11-18 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 1,170,000 | 0.12 | 137.5K | 71,845,493 | — | ↗ |
| 2013-11-15 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 318,050 | 0.12 | 37.3K | 24,095,113 | — | ↗ |
| 2013-11-15 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 318,050 | 0.12 | 37.3K | 16,063,408 | — | ↗ |
| 2013-11-15 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 318,050 | 0.12 | 37.3K | 73,015,493 | — | ↗ |
| 2013-11-15 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 253,050 | 0.12 | 29.7K | 72,950,493 | — | ↗ |
| 2013-11-14 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 465,090 | 0.12 | 53.6K | 24,200,069 | — | ↗ |
| 2013-11-14 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 465,090 | 0.12 | 53.6K | 16,133,379 | — | ↗ |
| 2013-11-14 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 465,090 | 0.12 | 53.6K | 73,333,543 | — | ↗ |
| 2013-11-14 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 465,090 | 0.12 | 53.6K | 73,333,543 | — | ↗ |
| 2013-11-11 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 39,000 | 0.12 | 4.8K | 21,535,048 | — | ↗ |
| 2013-11-11 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 39,000 | 0.12 | 4.8K | 15,792,808 | — | ↗ |
| 2013-11-11 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 39,000 | 0.12 | 4.8K | 71,785,493 | — | ↗ |
| 2013-11-11 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 39,000 | 0.12 | 4.8K | 71,785,493 | — | ↗ |
| 2013-11-06 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 122,200 | 0.12 | 15.1K | 22,139,590 | — | ↗ |
| 2013-11-06 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 122,200 | 0.12 | 15.1K | 16,235,699 | — | ↗ |
| 2013-11-06 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 122,200 | 0.12 | 15.1K | 73,798,633 | — | ↗ |
| 2013-11-06 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 122,200 | 0.12 | 15.1K | 73,798,633 | — | ↗ |
| 2013-10-29 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 139,800 | 0.13 | 17.8K | 22,176,250 | — | ↗ |
| 2013-10-29 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 102,520 | 0.01 | 1.3K | 16,262,583 | — | ↗ |
| 2013-10-29 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 466,000 | 0.13 | 59.2K | 73,920,833 | — | ↗ |
| 2013-10-29 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 466,000 | 0.13 | 59.2K | 73,920,833 | — | ↗ |
| 2013-10-28 | NIGALAYE ASHOK G | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 139,500 | 0.13 | 18.1K | 22,316,050 | — | ↗ |
| 2013-10-28 | NARINE JEENARINE | Director / 10% Owner | S-Sale | D | Common Stock | 102,300 | 0.13 | 13.2K | 16,365,103 | — | ↗ |
| 2013-10-28 | EPIC PHARMA LLC | 10% Owner | S-Sale | D | Common Stock | 465,000 | 0.13 | 60.2K | 74,386,833 | — | ↗ |
| 2013-10-28 | EPIC INVESTMENTS, LLC | 10% Owner | S-Sale | D | Common Stock | 465,000 | 0.13 | 60.2K | 74,386,833 | — | ↗ |
| 2013-09-10 | NIGALAYE ASHOK G | Director / Officer | C-Conversion | D | Series E Convertible Preferred Stock | 1,600 | 0.02 | 38.88 | 0 | — | ↗ |
| 2013-09-10 | NARINE JEENARINE | Director | C-Conversion | A | Common Stock | 14,485,597 | 0.02 | 352.0K | 16,467,403 | — | ↗ |
| 2013-09-10 | EPIC PHARMA LLC | 10% Owner | C-Conversion | A | Common Stock | 65,843,621 | 0.02 | 1.60M | 74,851,833 | — | ↗ |
| 2013-09-10 | EPIC INVESTMENTS, LLC | 10% Owner | C-Conversion | A | Common Stock | 65,843,621 | 0.02 | 1.60M | 74,851,833 | — | ↗ |
| 2013-08-01 | Hakim Nasrat A | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 9,097,561 | — | ↗ |
| 2013-07-23 | Plassche Douglas | Officer | A-Award | A | Options | 3,000,000 | 0.07 | 210.0K | 3,000,000 | — | ↗ |
| 2013-05-09 | POTTI RAM | 10% Owner | D-Return | D | Common Stock | 391,500 | 0.07 | 27.8K | 15,235,392 | — | ↗ |
Executive team
Top executives
EBIT / Employee
780.6K
Shares Outstanding
1.08B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2013 | Chris Dick President and Chief Operating Officer | 201.3K | — | — | — | — | 8.4K | 209.7K | 0.00% | ↗ |
| 2 | 2013 | Carter J. Ward Chief Financial Officer Secretary and Treasurer | 151.3K | — | — | — | — | — | 151.3K | 0.00% | ↗ |
| 3 | 2013 | Jerry Treppel Chairman of the Board and Chief Executive Officer | — | — | — | — | — | 30.0K | 30.0K | 0.00% | ↗ |
| 4 | 2012 | Chris Dick President and Chief Operating Officer | 200.0K | — | — | — | — | 8.4K | 208.4K | 0.00% | ↗ |
| 5 | 2012 | Carter J. Ward Chief Financial Officer Secretary and Treasurer | 150.0K | 600.00 | — | — | — | — | 150.6K | 0.00% | ↗ |
| 6 | 2012 | Jerry Treppel Chairman of the Board and Chief Executive Officer | — | — | — | — | — | 30.0K | 30.0K | 0.00% | ↗ |
| 7 | 2011 | Chris Dick President and Chief Operating Officer | 200.0K | — | — | — | — | 8.4K | 208.4K | 0.00% | ↗ |
| 8 | 2011 | Carter J. Ward Chief Financial Officer Secretary and Treasurer | 150.0K | 600.00 | — | — | — | — | 150.6K | 0.00% | ↗ |
| 9 | 2011 | Jerry Treppel Chairman of the Board and Chief Executive Officer | — | — | — | — | — | 30.0K | 30.0K | 0.00% | ↗ |
| 10 | 2010 | Chris Dick President and Chief Operating Officer | 218.8K | — | — | 18.7K | — | 8.4K | 245.9K | 7.60% | ↗ |
| 11 | 2010 | Carter J. Ward Chief Financial Officer Secretary and Treasurer | 105.0K | 500.00 | — | 18.7K | — | — | 124.2K | 15.05% | ↗ |
| 12 | 2010 | Jerry Treppel Chairman of the Board and Chief Executive Officer | — | — | — | — | — | 27.5K | 27.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nasrat Hakim | Chairman, Chief Executive Officer & President | 1M | male |
| Douglas Plassche | Executive Vice President of Operations | 526.7K | male |
| Carter J. Ward CSCP | Chief Financial Officer, Secretary & Treasurer | 413.2K | male |
| George Kenneth Smith | Vice President of Legal | 412.0K | — |
| Kirko Kirkov | Chief Commercial Officer | 195.4K | male |
| Dianne Will | Vice President of Investor Relations & Corporation Affairs | — | female |
| Christopher C. Dick | Head of Development | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELTP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
